Design: Cases and controls, observational study.
excessive production of thyroid hormones, the first cause of hyperthyroidism. These patients usually develop extrathyroidal manifestations, mainly GO, which is secondary to an inflammation of the orbital connective tissue and extraocular muscles (2) . In contrast, HT is characterized by a cellular autoimmune response, with a strong inflammatory cell infiltrate, which leads to destruction of the thyroid gland. HT is the most common cause of hypothyroidism (3) .
The interaction of thyroidal follicular cells, antigenpresenting cells, and autoreactive T and B lymphocytes accounts for the development of AITD, which is mediated by different T helper cell (Th) subsets, mainly Th1, Th2, and Th17 (4, 5) . In this regard, in patients with HT, a Th1/Th17 response predominates with a strong inflammatory cell infiltrate in thyroid tissue, whereas a Th2 response is the prevailing mechanism observed in patients with GD/GO. The evaluation of these T-cell subsets in AITD has attracted relevant attention in recent years to identify the main mechanisms involved in thyroid autoimmunity.
T regulatory (Treg) lymphocytes, through their ability to suppress immune responses, exert a relevant role in the pathogenesis of autoimmune and chronic inflammatory diseases (6) . Different subsets of Treg cells have been described (7, 8) , and some of them have previously been studied in patients with AITD, including the CD4 +
CD25
+ Foxp3 + and CD4 + CD69 + Foxp3 2 lymphocytes (9, 10) . In this regard, we have reported increased levels of CD25 + Foxp3 + Treg cells in patients with AITD, which were apparently unable to downmodulate the inflammatory and autoimmune response (9) . In addition, we have reported a decrease in CD69 + Tregs, which express constitutively the activation marker CD69, in AITD (10) . However, the levels and function of other CD4 + lymphocytes with immune-regulatory function have not been assessed in patients with thyroid autoimmunity. In this regard, it has been described that Treg type 1 (Tr1) cells are adaptive Treg cells characterized by the ability to secrete high levels of IL-10 and minimal amounts of IL-4 and IL-17 (11) . These regulatory cells are mainly induced in the periphery by IL-27, independently from the transcription factor Foxp3 (11) (12) (13) . Tr1 cells are able to suppress the function of Th lymphocytes and antigen-presenting cells mainly through the release of IL-10 and TGF-b. Recently, CD49b and LAG-3 have been identified as useful markers to identify Tr1 cells in humans (14) . Tr1 cells were identified .20 years ago, in the peripheral blood from patients with severe combined immunodeficiency after HLA-mismatched fetal liver hematopoietic stem cell transplant (15) . Since their discovery, Tr1 cells have been proven important in maintaining immunological homeostasis and preventing T-cell-mediated diseases (11) . Furthermore, the possibility to generate and expand Tr1 cells in vitro has led to a proposal for their use as cellular therapy in humans (15) .
The aim of this work was to assess the levels and function of Tr1 cells in patients with AITD. We found that the number of Tr1 cells was significantly diminished in the peripheral blood and thyroid tissue from patients with AITD and that these cells showed a defective suppressive function in vitro. In addition, we observed substantial associations among different clinical parameters and the levels of Tr1 cells.
Materials and Methods

Subjects
Thirty-eight patients with AITD (23 with GD and 15 with HT) and 26 healthy controls from the Endocrinology Service of the Hospital Universitario de la Princesa, Madrid, Spain, were studied. A total of 87% of patients with AITD were female, and 13% were male, with a mean age of 48 6 16 years (arithmetic mean 6 SD). Controls were age-and sex-matched, and none of them showed any evidence of a thyroid disorder. All patients with AITD were examined by an endocrinologist and fulfilled the criteria diagnostic for this condition. In addition, presence of goiter was assessed by palpation and echography. Furthermore, GO was evaluated by an ophthalmologist, and the activity of this condition was scored using Werner's no physical signs or symptoms, only signs, soft tissue involvement, proptosis, extraocular muscle signs, corneal involvement, and sight loss (NO SPECS) classification and the Clinical Activity Score (CAS) (16) . Active GO was defined when the CAS was .3.0, and inactive eye disease was defined as no changes in eye status over the previous 6 months. Five patients with HT underwent surgery because of large goiters. Complete clinical and demographic data were registered in all subjects (Table 1) , and a written informed consent was obtained from all of them. This study was approved by the Hospital Bioethical Committee.
Laboratory evaluation
Levels of thyroid hormones and thyroid autoantibodies were measured in serum samples from all patients with AITD as previously described (17) . Serum free T4 and TSH were measured by an electrochemiluminescence immunoassay (Elecsys 2010; Roche Diagnostics, Mannheim, Germany) with a reference range of 0.93 to 1.70 ng/dL, 0.27 to 4.20 mU/mL, and 3.5 to 77 ng/mL, respectively. Levels of TSH receptor (TSHRAb) were measured by ELISA (IASONTRAB, Graz-Seiersberg, Germany), with a reference range of ,0.05 U/L as negative and .0.7 U/L as positive. Titers of antithyroglobulin antibody (Tg-Ab) and anti-thyroperoxidase antibody (TPO-Ab) were determined by immunofluorometric assays (ImmunoCAP Thyroglobulin and Immuno-CAP Thyroid Peroxidase kits; Thermo Fisher Scientific, Waltham, MA). The reference range for Tg-Ab was ,40 IU/mL and for TPO-Ab ,25 IU/mL.
Cell isolation
Peripheral blood and thyroid gland tissue were obtained from patients with AITD and control subjects. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque (Lonza Ibérica, Barcelona, Spain) density-gradient centrifugation. Cellular viability was assessed by trypan blue dye exclusion, and it was always .95%. Mononuclear cells infiltrating the thyroid gland (TMCs) were isolated from surgical specimens from five patients with HT. Briefly, thyroid tissue was minced and digested with collagenase (1.0 mg/mL; Roche Molecular Biochemicals, Mannheim, Germany) for 1 hour at 37°C and 5% CO 2 . Then, cells were passed through a steel mesh (BD Biosciences, San Jose, CA), and mononuclear thyroid cells were isolated by Ficoll-Paque density-gradient centrifugation. Afterward, TMCs were washed and resuspended in RPMI 1640 with GlutaMAX culture medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), penicillin (50 IU/mL), and streptomycin (50 mg/mL) (Sigma-Aldrich). Although tissue samples from patients with GD (n = 4) or goiter (n = 2) were also obtained, not enough numbers of TMCs could be obtained in any case for their analysis.
Tr1 cell quantification
Levels of Tr1 cells were evaluated by a multiparametric flow cytometry analysis by using the following monoclonal antibodies (mAbs): CD4-PerCP (BD Biosciences), CD49b-APC (allophycocyanin) (BioLegend, San Diego, CA), and LAG-3 (CD223)-fluorescein isothiocyanate (BioLegend). Then, cells were fixed, permeabilized with paraformaldehyde 4% for 15 minutes at 4°C and saponine 0.1% for 10 minutes, and additionally stained with an anti-IL-10-phycoerythrin mAb (BioLegend). In a first analysis, all patients' data were mixed (GD and HT). On a posterior analysis, they were classified by specific disease. Data were acquired on an FACSCanto flow cytometer (BD Biosciences), and data were analyzed using FlowJo software v7.6 (Tree Star, Ashland, OR).
Analysis of Tr1 cell function
Suppressive function of Tr1 cells was analyzed by an assay of inhibition of cellular activation. Briefly, PBMCs of patients with GD were labeled with an anti-CD4/PerCP (BD Biosciences), anti-CD49b/APC (allophycocyanin) (BioLegend), and anti-LAG-3/fluorescein isothiocyanate mAb (BioLegend) for 30 minutes at 4°C. Then, an aliquot of PBMC was depleted from CD4 + CD49 + LAG-3 + cells by using an FACSAria II cell sorter (BD Biosciences), always obtaining a cellular purity .95%. Then, depleted and nondepleted cells were stimulated by culturing in 96-well plates (Costar, Corning, NY) precoated for 1.5 hours with an anti-CD3 (5.0 mg/mL; BioLegend) and an anti-CD28 (5.0 mg/mL; Immunotech, Marseille, France) mAb. Afterward, cells were incubated for 7 hours in OpTmizer CTS T cell expansion basal medium (Gibco by Life Technologies, Gaithersburg, MD) at 37°C and 5% CO 2 . At the start of the cell culture, an anti-CD40L/phycoerythrin mAb (BD Biosciences) was added (18, 19) , and at the end of incubation, cells were washed and analyzed for CD40L expression in an FACSCanto II flow cytometer (BD Biosciences). Results were expressed as the percentage of suppression of cellular activation, according to the following formula: 100 2 ([percentage of divided cells in the presence of Tr1/percentage of divided cells in the absence of Tr1] 3 100).
Measurement of cytokines
Levels of different cytokines were determined in supernatants of PBMC cultures depleted or not of Tr1 cells as stated above but incubated for 24 hours. Cytokine levels were determined by using a human FlowCytomix kit (eBioscience, Vienna, Austria). Detected cytokines were: interferon-g, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-22, and TNF-a. Data were acquired in an FACSCanto II cytometer and analyzed with FlowCytomix software. b TSH (0.27-4.3 mU/mL).
c TPO-Ab (negative ,100 UI/mL).
d Tg-Ab (negative ,344 UI/mL).
e TSHR-Ab (negative ,0.5 U/L).
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Immunofluorescence analysis
Immunofluorescence analysis was performed in 4.0-mmthick thyroid tissue sections of patients with HT who were submitted for total or partial thyroidectomy. These sections were labeled with anti-CD49b (Santa Cruz Biotechnology, Dallas, TX) and anti-LAG-3 (Santa Cruz
Statistical analysis
All data were expressed as the arithmetic mean 6 SD or as median and interquartile range, according to their normal or not normal distribution, respectively. Student t test, KruskalWallis test, and one-way ANOVA tests were used for comparisons among groups. Spearman or Pearson correlation tests were used for association analysis. All data were analyzed using GraphPad Prism software, v5.0 (GraphPad Software, San Diego, CA).
Results
Tr1 cells are diminished in patients with AITD
To evaluate the levels of Tr1 cells, we performed a multiparametric analysis staining with anti-CD4, CD49b, LAG-3, and IL-10 mAb and then selected the CD4 + CD49b + cells and later LAG-3 + IL-10 + cells, as shown in Fig. 1A and 1B. We found a decreased percentage of Tr1 cells (CD4 + CD49b + LAG-3 + IL-10 + ) in the peripheral blood from patients with AITD in comparison with healthy controls (P , 0.001; Fig. 1C) . Likewise, the absolute number of these regulatory lymphocytes was also significantly diminished in patients with AITD compared with healthy subjects (P , 0.001; Fig. 1D ). Subsequent analysis showed that this decreased number of Tr1 cells was detected in both patients with HT and GD in comparison with healthy subjects (P , 0.001 and P , 0.005, respectively; Fig. 1E and 1F) . Accordingly, similar proportions and absolute numbers of Tr1 cells were observed in patients with HT and GD (P . 0.05 in both cases; Fig. 1E and 1F ). Finally, we performed a correlation analysis between different clinical or laboratory parameters and the levels of Tr1 lymphocytes. As shown in Fig. 2A , an apparent association between the time of disease evolution and the number of Tr1 cells was observed; however, we only detected a borderline value of P in this analysis (r = 0.48; P = 0.052), indicating that it would be convenient to further assess this point by increasing the number of individuals studied. In contrast, we found a very noteworthy (and unexpected) association between the levels of anti-TSHR-Abs and the percent of Tr1 cells (r = 0.72; P , 0.001; Fig. 2B ). Moreover, a positive correlation between CAS and Tr1 cell levels was also detected (r = 0.47; P = 0.044; Fig. 2C ). Additional analyses did not detect tendencies of association of potential interest or notable correlations between the levels (percent or absolute number) of Tr1 cells and other clinical or laboratory parameters (data not shown).
Tr1 cells in thyroid tissue from patients with AITD
When the possible presence of Tr1 cells in thyroid gland was analyzed by both flow cytometry and immunofluorescence microscopy, we were unable to detect these lymphocytes in tissue samples from controls (goiter) or patients with GD without inflammatory cell infiltrate (data not shown). In contrast, in tissue samples from patients with HT, we easily detected the presence of Tr1 lymphocytes by flow cytometry (Fig. 3A and 3B ) and immunofluorescence microscopy ( Fig. 3C-3E) . However, when the percentage of Tr1 lymphocytes in mononuclear cells isolated from thyroid tissue was compared with that detected in peripheral blood from the same individuals (referred to as TMCs and PBMCs, respectively), considerably lower numbers were observed in thyroid tissue (Fig. 3F ).
Tr1 cells show a deficient suppressive function in patients with AITD
The regulatory function of Tr1 cells was analyzed by an assay of suppression of activation of autologous lymphocytes by measuring the expression of CD40L in PBMCs depleted or not of Tr1 cells (Fig. 4A) . As expected, we found a substantial increase in CD40L expression when Tr1 cells were removed in both controls and patients (P , 0.001 and P , 0.005, respectively; Fig. 4B ). However, the percentage of suppression by Tr1 cells was lower in patients with AITD compared with healthy controls (P = 0.0104; Fig. 4C ) and in both HT and GD (data not shown). In addition, when the suppressive activity of Tr1 cells on cytokine release was analyzed, we found a significant inhibition of the release of the proinflammatory cytokines IL-1b, IL-13, TNF-a, and IL-12 in cell cultures from healthy subjects ( Fig. 5 ; P , 0.05 in all cases). In contrast, in cell cultures from patients with AITD, we did not observe a significant inhibition in the synthesis of IL-1b and TNF-a ( Fig. 5 ; P . 0.05 in both cases). In the case of the other cytokines analyzed (interferon-g, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, and IL-22), no noteworthy inhibition by Tr1 lymphocytes was observed in cells cultures from patients with AITD or controls (data not shown).
Discussion
Loss of immune tolerance to self-thyroid antigens, including thyroglobulin, TPO, and TSHR, allows the development of AITD, which mainly comprise GD, GO, and HT (5, 20) . In this regard, the involvement of several subsets of autoreactive Th and Treg cells in the pathogenesis of AITD has been previously analyzed (21 + cells), also participate in the pathogenesis of the immune dysregulation observed in patients with AITD. This point is supported by the functional analysis of these cells, which showed a defective ability to suppress the activation of conventional T lymphocytes as well as the release of the proinflammatory cytokines IL-1b and TNF-a in patients with AITD. We consider of interest the scarcity of Tr1 cells in the inflammatory cell infiltrate of the thyroid gland of patients with AITD. In this regard, it is very feasible that this finding is closely related to the low number of these regulatory lymphocytes in the peripheral blood, a finding that in turn could be due to a defective differentiation of them in lymphoid tissues. It is also possible that circulating microvesicles could affect the differentiation of Tr1 cells, as we have previously observed for CD4 + Foxp3 + Treg lymphocytes (32) .
However, it is of interest that in the case of CD4 + Foxp3 + and CD4 + CD69 + Treg cells, there are more of them in the inflamed thyroid tissue (9, 10) . Thus, the migratory behavior toward the thyroid gland of the distinct Treg cell subsets seems to be different in AITD, a phenomenon that could be related to the synthesis of certain chemokines into the inflammatory cell infiltrate. Another interesting finding of this study was the notable positive correlation detected between the number of Tr1 cells and the levels of TSHR-Abs in patients with GD. We consider that this is an unexpected finding, because more regulatory cells should favor the negative regulation of the autoimmune process and would produce a diminution of autoantibody synthesis. Thus, although we do not have a plausible explanation for this finding, it is feasible that the ongoing autoimmune response observed in patients with GD might stimulate the differentiation of Tr1 cells and their migration to the bloodstream. However, according to our data, these cells exert a defective regulatory function, a phenomenon that might contribute to the persistence of the autoimmune response. Therefore, we consider that this finding is interesting and requires further investigation.
In conclusion, we consider that the data of this study add another relevant immune dysfunction in patients with AITD (i.e., a reduced number of Tr1 lymphocytes accompanied by a defective function of these cells), a phenomenon that could be important in the pathogenesis of these autoimmune conditions.
